ANI Pharmaceuticals vs Prestige Consumer Healthcare
Prestige Consumer Healthcare is the larger business, with $1.09bn of revenue in fiscal 2026 against $883m for ANI Pharmaceuticals (1.2 times as much). ANI Pharmaceuticals grew faster (43.8% against -4.3%). Prestige Consumer Healthcare kept more of each dollar of sales as profit: a net margin of 17.5% against 8.9%.
| Latest fiscal year | ANI PharmaceuticalsANIP, 2025 | Prestige Consumer HealthcarePBH, 2026 |
|---|---|---|
| Revenue | $883m | $1.09bn |
| Revenue growth | 43.8% | -4.3% |
| Net income | $78.3m | $190m |
| Operating margin | — | — |
| Net margin | 8.9% | 17.5% |
| Return on equity | 16.6% | 10.2% |
| Free cash flow | $171m | $246m |
| Cash | $286m | $63.9m |
| Total debt | $309m | $1.00bn |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | $12.2m | $156m |
| Employees | 970 | 890 |
| Market value | $1.61bn | $2.34bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 45 (Weak) | 67 (Moderate) |
| Insider trades, 12 months | 0 buys, 50 sales | 0 buys, 8 sales |